Hanmi Pharmaceutical Co. Ltd. has described son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer.

The definitive diagnosis was established through extensive histopathological examination and immunohistochemistry, which demonstrated the tumour’s unique immunoprofile, showing strong positivity for ...

Boehringer and MD Anderson said the new agreement allows them to research a first in first-in-class SOS1 pan-KRAS inhibitor known as BI 1701963. They will also work on an inhibitor of KRAS G12C ...

including pancreatic and colorectal cancer - and SOS1 inhibitor MRTX0902, designed to boost the activity of KRAS-targeting drugs. “With multiple targeted oncology assets including Krazati ...

Bayer will provide insights into the discovery and characterization of its investigational oral selective Son of Sevenless Homologue 1 (SOS1) inhibitor BAY 3498264, which is currently being evaluated ...